GENEREX Trademark

Trademark Overview

On Friday, February 8, 2002, a trademark application was filed for GENEREX with the United States Patent and Trademark Office. The USPTO has given the GENEREX trademark a serial number of 76368568. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Tuesday, May 27, 2008. This trademark is owned by Collateral Therapeutics, Inc.. The GENEREX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment of cardiovascular disorders, for stimulation of blood vessel growth and for gene therapy, excluding pharmaceuticals or vaccines used in the treatment or prevention of Hepatitis
generex

General Information

Serial Number76368568
Word MarkGENEREX
Filing DateFriday, February 8, 2002
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateTuesday, May 27, 2008
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 5, 2003

Trademark Statements

Goods and ServicesPharmaceuticals for use in the treatment of cardiovascular disorders, for stimulation of blood vessel growth and for gene therapy, excluding pharmaceuticals or vaccines used in the treatment or prevention of Hepatitis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, February 20, 2002
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCARDIUM THERAPEUTICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressSAN DIEGO, CA 92130
Party NameCollateral Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130
Party NameCollateral Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events

Event DateEvent Description
Wednesday, August 13, 2008ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Wednesday, August 13, 2008ABANDONMENT - NO USE STATEMENT FILED
Friday, December 28, 2007EXTENSION 5 GRANTED
Wednesday, November 21, 2007EXTENSION 5 FILED
Thursday, November 29, 2007PAPER RECEIVED
Saturday, August 25, 2007EXTENSION 4 GRANTED
Thursday, May 24, 2007EXTENSION 4 FILED
Tuesday, May 29, 2007PAPER RECEIVED
Friday, January 26, 2007EXTENSION 3 GRANTED
Wednesday, November 22, 2006EXTENSION 3 FILED
Monday, November 27, 2006PAPER RECEIVED
Tuesday, June 20, 2006EXTENSION 2 GRANTED
Wednesday, May 24, 2006EXTENSION 2 FILED
Friday, May 26, 2006PAPER RECEIVED
Friday, April 28, 2006EXTENSION 1 GRANTED
Thursday, November 24, 2005EXTENSION 1 FILED
Tuesday, April 11, 2006PETITION TO REVIVE-GRANTED
Wednesday, March 29, 2006PETITION TO REVIVE-RECEIVED
Wednesday, March 29, 2006PAPER RECEIVED
Monday, January 23, 2006ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, January 23, 2006ABANDONMENT - NO USE STATEMENT FILED
Tuesday, May 24, 2005NOA MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 8, 2004OPPOSITION TERMINATED NO. 999999
Friday, November 19, 2004OPPOSITION DISMISSED NO. 999999
Tuesday, December 16, 2003OPPOSITION INSTITUTED NO. 999999
Monday, September 15, 2003EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, August 5, 2003PUBLISHED FOR OPPOSITION
Wednesday, July 16, 2003NOTICE OF PUBLICATION
Friday, June 6, 2003APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 22, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 11, 2002ASSIGNED TO EXAMINER
Wednesday, May 22, 2002LETTER OF SUSPENSION MAILED
Friday, May 3, 2002ASSIGNED TO EXAMINER

Related Keywords

generex pharmaceuticals treatment excluding vaccines prevention hepatitis therapy used growth disorders